CD47 and neoplasm: In vivo, combining LSD1 inhibitors with anti-CD47/PD-L1 antibodies in TC-1 tumor-bearing mice significantly inhibits tumor growth by enhancing immune activation and reducing CD47 and PD-L1 signaling.